Evaluating outcomes of mother–infant pairs using dolutegravir for HIV treatment during pregnancy

OBJECTIVES: Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we assess maternal and infant outcomes of mother–infant pairs using DTG-containing regimens during pregnancy. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Grayhack, Clara, Sheth, Anandi, Kirby, Olivia, Davis, Jennifer, Sibliss, Kedesha, Nkwihoreze, Hervette, Aaron, Erika, Alleyne, Gregg, Laguerre, Roberta, Rana, Aadia, Badell, Martina, Momplaisir, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Clinical Science: Concise Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125741/
https://www.ncbi.nlm.nih.gov/pubmed/29944472
http://dx.doi.org/10.1097/QAD.0000000000001931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125741/
https://www.ncbi.nlm.nih.gov/pubmed/29944472
http://dx.doi.org/10.1097/QAD.0000000000001931

Ejemplares similares